Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 5/20 | 0.36 |
| ▸ | CD74 | P04233 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 6/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32674510 | 0.80 | MAPT (0.41) | MIFCD74ALDH1A1 | |
| SCHEMBL32674261 | 0.77 | KMT2A (0.44) | MIFCD74KMT2AIDO1POLB | |
| SCHEMBL32674496 | 0.77 | KMT2A (0.44) | MIFCD74KMT2AIDO1POLB | |
| SCHEMBL32674425 | 0.73 | KMT2A (0.45) | MIFCD74KMT2AIDO1POLB | |
| SCHEMBL32674477 | 0.70 | MCL1 (0.39) | KMT2AMEN1TP53 | |
| SCHEMBL32674302 | 0.70 | DDB1 (0.38) | ALDH1A1 | |
| SCHEMBL32674374 | 0.61 | KMO (0.45) | MIFCD74KMT2AIDO1MEN1 | |
| SCHEMBL29009118 | 0.60 | CYP19A1 (0.53) | KMT2AIDO1POLBMEN1ALDH1A1 | |
| SCHEMBL32674486 | 0.59 | ALDH1A1 (0.41) | MIFCD74KMT2AIDO1POLB | |
| SCHEMBL16186529 | 0.59 | KMO (0.39) | KMT2AIDO1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | TRIANA BIOMEDICINES, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260042752-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | TRIANA BIOMEDICINES INC (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042752-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | ALK, NTRK1, NTRK3 | MIF 4562/4885CD74 3307/4885KMT2A 1251/4885 |
| US-12565492-B2 | Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof | ALK, NTRK3, NTRK1 | MIF 3616/4885CD74 3646/4885KMT2A 2256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.